Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,190,160
  • Shares Outstanding, K 2,537,829
  • Annual Sales, $ 50,266 M
  • Annual Income, $ 5,844 M
  • EBIT $ 6,104 M
  • EBITDA $ 17,131 M
  • 60-Month Beta 0.61
  • Price/Sales 2.88
  • Price/Cash Flow 8.27
  • Price/Book 1.70

Options Overview Details

View History
  • Implied Volatility 28.86% ( +4.04%)
  • Historical Volatility 18.90%
  • IV Percentile 80%
  • IV Rank 51.95%
  • IV High 39.81% on 04/24/24
  • IV Low 17.02% on 03/11/24
  • Put/Call Vol Ratio 1.04
  • Today's Volume 49
  • Volume Avg (30-Day) 657
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 37,481
  • Open Int (30-Day) 40,518

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.91
  • Number of Estimates 4
  • High Estimate 0.97
  • Low Estimate 0.83
  • Prior Year 0.89
  • Growth Rate Est. (year over year) +2.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.00 +5.90%
on 10/24/24
56.15 -5.70%
on 10/09/24
-2.52 (-4.54%)
since 10/04/24
3-Month
50.00 +5.90%
on 10/24/24
58.97 -10.21%
on 09/04/24
-0.10 (-0.19%)
since 08/02/24
52-Week
45.00 +17.66%
on 11/07/23
58.97 -10.21%
on 09/04/24
+7.15 (+15.61%)
since 11/03/23

Most Recent Stories

More News
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...

BAYRY : 6.7600 (-0.59%)
NVS : 110.52 (+1.07%)
REGN : 828.84 (-1.75%)
SNY : 52.95 (-0.60%)
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

One of these players has split its stock in the past. The other one hasn't.

NVDA : 136.05 (+0.48%)
LLY : 806.14 (-1.56%)
GS : 511.47 (-1.52%)
CMG : 56.38 (-3.77%)
REGN : 828.84 (-1.75%)
AMGN : 316.91 (-0.72%)
WMT : 82.45 (+0.32%)
SNY : 52.95 (-0.60%)
Why Sanofi Stock Flew Higher on Friday

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

SNY : 52.95 (-0.60%)
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive talks with U.S. private equity company CD&R to sell a controlling stake in its...

AZN : 71.43 (+0.01%)
NVO : 109.72 (-1.98%)
RHHBY : 39.4300 (+0.43%)
PFE : 27.76 (-1.17%)
SNY : 52.95 (-0.60%)
Sanofi (SNY) Q3 2024 Earnings Call Transcript

SNY earnings call for the period ending September 30, 2024.

SNY : 52.95 (-0.60%)
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales

Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks Consensus Estimate of $1.35 per share. Earnings of €2.86 per share rose 12.2% on...

AZN : 71.43 (+0.01%)
LLY : 806.14 (-1.56%)
REGN : 828.84 (-1.75%)
SNY : 52.95 (-0.60%)
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi

For Immediate ReleaseChicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

JNJ : 158.24 (-1.18%)
ABBV : 200.47 (-1.51%)
RHHBY : 39.4300 (+0.43%)
PFE : 27.76 (-1.17%)
SNY : 52.95 (-0.60%)
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC)...

JNJ : 158.24 (-1.18%)
GSK : 36.97 (+0.24%)
PFE : 27.76 (-1.17%)
SNY : 52.95 (-0.60%)
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

Let's look beyond this piece of bad news from regulators.

NVAX : 9.12 (-2.46%)
SNY : 52.95 (-0.60%)
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs

This week, Johnson & Johnson JNJ began the third-quarter earnings season for the drug and biotech sector. The FDA granted approval to a few new drugs, which included Pfizer’s PFE gene therapy for hemophilia,...

JNJ : 158.24 (-1.18%)
ABBV : 200.47 (-1.51%)
RHHBY : 39.4300 (+0.43%)
PFE : 27.76 (-1.17%)
SNY : 52.95 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 54.17
2nd Resistance Point 53.86
1st Resistance Point 53.41
Last Price 52.95
1st Support Level 52.65
2nd Support Level 52.34
3rd Support Level 51.89

See More

52-Week High 58.97
Fibonacci 61.8% 53.63
Last Price 52.95
Fibonacci 50% 51.99
Fibonacci 38.2% 50.34
52-Week Low 45.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar